158 related articles for article (PubMed ID: 23773507)
1. Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
Tavil B; Erdem AY; Azik F; Isik P; Metin A; Emir S; Uckan D; Tunc B
Pediatr Transplant; 2013 Sep; 17(6):E146-8. PubMed ID: 23773507
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of non-Hodgkin's lymphoma using R-CHOP in a patient with Wiskott-Aldrich syndrome followed by a reduced-intensity stem cell transplant.
Koga Y; Takada H; Suminoe A; Ohga S; Hara T
Pediatr Transplant; 2014 Sep; 18(6):E208-11. PubMed ID: 24930759
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
7. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
[TBL] [Abstract][Full Text] [Related]
8. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
10. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
[TBL] [Abstract][Full Text] [Related]
11. Successful allogeneic peripheral blood stem cell transplantation in Wiskott-Aldrich Syndrome Patients: first report in Thailand.
Hongeng S; Benjaponpitak S; Tardtong P; Varavithya W; Chuansumrit A; Chunharas A; Chaisiripoomkere W; Hathira P
Asian Pac J Allergy Immunol; 2001 Sep; 19(3):191-5. PubMed ID: 11826914
[TBL] [Abstract][Full Text] [Related]
12. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
13. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
14. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
15. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Bornhäuser M; Thiede C; Schuler U; Platzbecker U; Freiberg-Richter J; Helwig A; Plettig R; Röllig C; Naumann R; Kroschinsky F; Neubauer A; Ehninger G
Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
[TBL] [Abstract][Full Text] [Related]
16. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
[No Abstract] [Full Text] [Related]
17. Hematopoietic stem cell transplantation from a donor with Klinefelter syndrome for Wiskott-Aldrich syndrome.
Balci YI; Turul T; Daar G; Anak S; Devecioglu O; Tezcan I; Cetinkaya DU
Pediatr Transplant; 2008 Aug; 12(5):597-9. PubMed ID: 18331539
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
19. Successful Reduced Intensity Allogeneic Transplant With Full Donor Chimerism and Good Quality of Life in Adolescent Patient With Wiskott-Aldrich Syndrome.
Ali S; Gacsadi A; McDougall E; Armstrong C; Krueger J; Schechter T; Ali M
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e267-e269. PubMed ID: 28538502
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of X-linked polymorphic loci as gene markers to track X allele and chimerism in a post-allogeneic peripheral blood stem cell transplant patient with Wiskott-Aldrich syndrome.
Sasanakul W; Hongeng S; Chuansumrit A; Chaiyaratana W; Pakakasama S; Hathirat P
J Med Assoc Thai; 2001 Mar; 84(3):379-84. PubMed ID: 11460939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
